This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of -3.03% and 16.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 16.52% and 2.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC (MGTX) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 55.10% and 202.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 0% and 79.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -13.46% and 38.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q3 Earnings Expected to Decline
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
by Kinjel Shah
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 13.21% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC (MGTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -25.58% and 83.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx (MGTX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
MeiraGTx Holdings (MGTX) has been struggling lately, but the selling pressure may be coming to an end soon
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to Decline
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Buy Stocks For July 10th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
MeiraGTx Holdings PLC (MGTX) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Abeona Treats First Patient in Pivotal Gene Therapy Study
by Zacks Equity Research
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.
What Makes MeiraGTx Holdings PLC (MGTX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does MeiraGTx Holdings PLC (MGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
Gene Therapy the Next Best Thing: Here's Why (Revised)
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Gene Therapy the Next Best Thing: Here's Why
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences